Clinical-stage biotechnology company leveraging computational approaches to discover and develop new medicines.
Relay Therapeutics, Inc. operates as a cutting-edge clinical-stage precision medicines company at the forefront of transforming drug discovery. Established in 2015 and based in Cambridge, Massachusetts, the company is dedicated to advancing small molecule therapeutic discovery with a primary focus on targeted oncology and genetic diseases.
Central to Relay Therapeutics' innovative pipeline are several lead product candidates. Among them is RLY-4008, an oral small molecule inhibitor targeting fibroblast growth factor receptor 2 (FGFR2). Currently in a first-in-human clinical trial, RLY-4008 aims to address advanced or metastatic FGFR2-altered solid tumors. Additionally, RLY-2608 represents a leading mutant-PI3Ka inhibitor program designed to target phosphoinostide 3 kinase alpha, while RLY-1971, an oral small molecule inhibitor of protein tyrosine phosphatase Src homology region 2 domain-containing phosphatase-2, is undergoing Phase 1 trials for patients with advanced solid tumors.
Collaboration and innovation are key pillars of Relay Therapeutics' strategy. The company has established strategic partnerships, including collaboration and license agreements with D. E. Shaw Research, LLC, leveraging advanced computational modeling capabilities to analyze protein motion and enhance the development of compounds targeting specific biological targets. Furthermore, Relay Therapeutics collaborates with Genentech, Inc. for the development and commercialization of RLY-1971, underscoring its commitment to expanding therapeutic options through synergistic partnerships.
Formerly known as Allostery, Inc., Relay Therapeutics rebranded in December 2015 to reflect its focus on leveraging protein motion dynamics in drug discovery. With its headquarters in Cambridge, Massachusetts, Relay Therapeutics continues to pioneer precision medicine approaches, aiming to deliver transformative therapies that improve outcomes for patients globally.